Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8
- Resource Type
- Article
- Source
- In
The Breast December 2023 72 - Subject
- Language
- ISSN
- 0960-9776